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ILR Special Issue
FOREWORD
This special issue of the Loyola of Los Angeles International and
Comparative Law Review brings together five essays on the national and
international legal aspects of the modification of the genome of human
germline cells (i.e. sperm and oocytes). They were written for a symposium scheduled for spring 2020, to be held at Loyola Law School, Los
Angeles, to launch the book Human Germline Genome Modification and
the Right to Science: A Comparative Study of National Laws and Policies
(Boggio, Romano, & Almqvist eds., Cambridge University Press, 2019).
As the COVID-19 pandemic started claiming victims by the thousands
across the globe, the symposium was hastily called off, but publication of
the symposium essays went ahead. The pandemic and the disconnected
initial international response provided yet another stark reminder of the
importance of international cooperation in the field of medicine and biotechnology.
Over the past twenty-five years, biotechnology has enormously expanded the capacity to manipulate the building blocks of all life, including humans. As early as 2000, Gregory Stock and John Campbell noted
that the achievement of the capacity to make changes to human germline
cells was “inevitable.”1 “The real question,” they postulated, was not
“whether the technology will become feasible, but when and how it
will.”2 The advent of the CRISPR/Cas9 family of genome editing tools
during the second half of the 2010s answered the question of how. As to
when, it was November 2018, when He Jianku, an associate professor in
the Department of Biology of the Southern University of Science and
Technology in Shenzhen, China, stunned the world by announcing that
he had used CRISPR/Cas9 to edit the genome of at least two human embryos. The world quickly condemned the rogue scientist, who was also
sanctioned by the Chinese government, but what was done could not be
undone and a new world had been ushered in, ready or not.
1. ENGINEERING THE HUMAN GERMLINE: AN EXPLORATION OF THE SCIENCE AND ETHICS
ALTERING THE GENES WE PASS TO OUR CHILDREN 6 (Gregory Stock & John Campbell eds.,
2000).
2. Id. at 5.
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For legal and ethical reasons explained in depth in the book,
germline gene therapies have not yet been legally clinically tested on humans, anywhere. However, basic research has made progress towards unlocking CRISPR-based germline gene therapies to eliminate a long list of
severe genetic disorders that claim or compromise the life of millions
around the world. Whether these therapies will be able to move “from
bench to bed,” to be clinically applied, depends on the regulatory frameworks that each State, and all of them collectively, has in place, and those
they will create in response to scientific, technological and legal challenges created by the application of CRISPR/Cas9 tools to the genome of
human germline cells.
The book analyzes how human germline genome modification is
currently regulated in a selected, but fairly broad and representative, set
of eighteen developed countries, and assesses these national governance
practices in the light of the existing and emerging international legal obligations states have, including, of course, the obligation to respect international human rights. The five pieces in this symposium issue revisit
some of the chapters in the book and add further material for discussion.
Santa Monica, CA, 26 February 2021
PROF. DR. CESARE P.R. ROMANO
Professor of Law and W. Joseph Ford Fellow
Loyola Law School, Los Angeles

